OTC Markets OTCQB - Delayed Quote USD

Evofem Biosciences, Inc. (EVFM)

Compare
0.0090 -0.0002 (-2.17%)
At close: September 26 at 4:00 PM EDT
Loading Chart for EVFM
DELL
  • Previous Close 0.0092
  • Open 0.0097
  • Bid 0.0092 x --
  • Ask 0.0095 x --
  • Day's Range 0.0092 - 0.0100
  • 52 Week Range 0.0060 - 0.2260
  • Volume 538,793
  • Avg. Volume 1,124,839
  • Market Cap (intraday) 902,960
  • Beta (5Y Monthly) -0.69
  • PE Ratio (TTM) 0.00
  • EPS (TTM) 6.5800
  • Earnings Date Nov 12, 2024 - Nov 18, 2024
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est --

Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. Its commercial product is Phexxi, a vaginal gel for the prevention of pregnancy. The company is also involved in the development of EVO100 for the prevention of chlamydia and gonorrhea in Women, and EVO200 for the prevention of recurrent bacterial vaginosis. Evofem Biosciences, Inc. is headquartered in San Diego, California.

www.evofem.com

37

Full Time Employees

December 31

Fiscal Year Ends

Recent News: EVFM

View More

Performance Overview: EVFM

Trailing total returns as of 9/26/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

EVFM
85.94%
S&P 500
20.45%

1-Year Return

EVFM
93.57%
S&P 500
32.46%

3-Year Return

EVFM
100.00%
S&P 500
28.95%

5-Year Return

EVFM
100.00%
S&P 500
92.48%

Compare To: EVFM

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: EVFM

View More

Valuation Measures

Annual
As of 9/26/2024
  • Market Cap

    923.02k

  • Enterprise Value

    49.01M

  • Trailing P/E

    0.00

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.52

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    2.77

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    341.16%

  • Return on Assets (ttm)

    -61.69%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    17.71M

  • Net Income Avi to Common (ttm)

    57.35M

  • Diluted EPS (ttm)

    6.5800

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    --

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    446.38k

Research Analysis: EVFM

View More

Company Insights: EVFM

Research Reports: EVFM

View More

People Also Watch